As per the evaluations of the TMR report, the global constipation treatment market was worth US$12.58 bn in 2016. During the forecast period of 2017 to 2025, the TMR report projects the global constipation treatment market to exhibit a healthy CAGR of 7.1%, estimating it to reach an overall valuation of US$22.93 bn by 2025.

Based on therapeutic option, the global constipation treatment market earns maximum demand for laxatives segment, which is further bifurcated into bulk forming agents, osmotic laxatives, and stimulant laxatives. The laxative segment is anticipated to experience incrementing demand at CAGR 7.0% during the forecast period, owing to low cost and wide availability. On the basis of disease type, the global market for constipation treatment has most prominent demand for opioid induced constipation (OIC), whereas hospitals continue to be the best distribution channel category. Geographically, although the developed region of North America is currently most lucrative, Asia Pacific has been projected as quickly emerge as highly profitable regional market during the forecast period.

View and Download TOC of Constipation Treatment Market Research Report @ http://www.transparencymarketresearch.com/report-toc/16442

Emerging Economies Opening New Opportunities for Market

Constipation is a common phenomenon, experienced by almost every individual at some point of their lifetime, if not frequently, and is evident in 8% to 32.5% of population across the globe. The choice of medicines to treat the constipation depends upon the type of constipation. Increasing geriatric population and changing dietary habits in developed as well developing markets is expected to increase the incidences of functional constipation across the globe in the near future. It is estimated that more than half of people above 50 years of age are prone to have chronic constipation. Moreover, leading industry players are investing on development of novel specialty constipation treatment drugs, which is anticipated to propel the growth of constipation treatment market. Surge in opioids consumption for relieving chronic pain is another favorable factors for the global constipation treatment market. There is high prevalence of irritable bowel syndrome in emerging markets such as Asia Pacific and Latin America. Around 35% IBS patients are likely to be affected with constipation (IBS-C). This high prevalence of IBS-C, OIC and chronic constipation is estimated to drive expansion of constipation treatment market across the globe.

Over-reliance on OTC Restraining Market Growth

The TMR report notes that despite a number of drivers and vast opportunities, the global constipation treatment market is hindered by the continuous reliance of a majority on over-the-counter (OTC) drugs, as well as on generic laxatives. In addition to that, the specialty constipation drugs have not reached every corner of the world due to the lack of proper healthcare infrastructure in various emerging economies. Though this may currently obstruct the market, the leading players will gain new opportunities if they strategically invest on reaching these unmet demands.

Request and Download Sample Report@ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16442

A freshly-compiled intelligence study by Transparency Market Research (TMR) has noted that a vast number of players are participating in the global constipation treatment market, which has been a prevalent disorder among the masses for several decades. With resilient research and development, latest drugs and treatment procedures have enabled caregivers to bring relief to the patients, and consequently opened widespread opportunities for the companies venturing in the constipation treatment market. The report identifies and profiles a number of key players who hold position of strength in the global constipation treatment market, including Bayer AG, Sanofi, Takeda Pharmaceuticals Company Limited, Sucampo Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., AstraZeneca, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Daewoong Pharmaceuticals Co. Ltd., Cosmo Pharmaceuticals NV, Prestige Brands Holdings, Inc., Janssen Pharmaceutical Company, Shionogi & Co., Ltd., Renexxion, LLC., and Albireo Pharma, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/